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The rising incidence of chronic-obstructive pulmonary
diseases is linked to the development of new human-
specific anti-inflammatory therapeutics. In many cases
classic rodent models fail to predict reliable data of
safety and efficacy, which contributes to a growing
demand of models that represent the human situation
in more detail e. g., anatomy and immune-response.
Similar to the human setting of segmental lipopolysac-
charide (LPS) challenge, we established a LPS induced
acute lung-inflammation model in the common marmo-
set monkey, a small non-human primate. LPS induced
inflammation mimics pro-inflammatory aspects of
chronic airway diseases associated with neutrophile
aggregation.
Healthy animals underwent a first BAL to obtain base-
line data. Marmosets were than pre-treated orally with
roflumilast (7 µg/kg bw), a recently approved PDE-4-
inhibitor, or dexamethasone (2 mg/kg bw) as a treat-
ment control on five consecutive days. Sham treated
animals served as positive control. Under general anaes-
thesia 500 ng LPS were instilled into the left half of the
lung of each animal, followed by ipsilateral BAL of the
LPS challenged lung 18 h post-provocation. BAL fluid
was processed and analysed for cellular and cytokine
levels. A whole blood assay performed on day 0 and
5 served as an additional readout.
As expected, LPS induced significant influx of total
cells into the airways (p<0.001) mainly through neutro-
phil aggregation. Pre-treatment with roflumilast resulted
in a statistically significant decrease of neutrophil num-
bers in BAL fluid (p=0.047). Dexamethasone pre-treat-
ment showed a significant reduction in relative cell
numbers (p=0.047), but not in absolute neutrophil num-
bers (p=0.076). TNF-a levels were significantly increased
after LPS provocation and significantly suppressed in
roflumilast (p=0.048) and dexamethasone (p=0.036) pre-
treated animals. In the WBA only pre-treatment with
dexamethasone resulted in a reduced TNF-a release
after ex vivo LPS provocation.
Results from this new translational nonhuman primate
model indicate the common marmoset monkey as a
promising species to test new anti-inflammatory drugs.
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